What is CORESTEMCHEMON Inc.'s (166480.KQ) StockRank?

MoatMap's StockRank for CORESTEMCHEMON Inc. (166480.KQ) is 9/100, with a Strong Sell signal. This is a composite score combining Quality (15), Value (45), and Momentum (33) factor ranks across MoatMap's 20,000+ stock universe.

Does CORESTEMCHEMON Inc. have an economic moat?

CORESTEMCHEMON Inc. (166480.KQ) has a Quality factor score of 15/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is CORESTEMCHEMON Inc. a buy, hold, or sell?

MoatMap's current signal for CORESTEMCHEMON Inc. (166480.KQ) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is CORESTEMCHEMON Inc. in?

CORESTEMCHEMON Inc. (166480.KQ) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

166480.KQ

STRONG SELLREMOVE

CORESTEMCHEMON Inc. · Healthcare · South Korea · $69M · Avg Vol: $2M/d

StockRank

P/E (TTM)

—

ROE

-66.1%

D/E

0.8x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

CORESTEMCHEMON is a South Korean stem cell biotech and CRO. It lacks the scale, global regulatory validation, and pricing power required to play our CDMO theme, and its extremely low quality score (15) is a major red flag.

COMPANY DESCRIPTION

CORESTEMCHEMON Inc. is a biotechnology company specializing in the development of stem cell therapies for rare diseases and the provision of non-clinical contract research organization (CRO) services. The company's competitive moat is anchored by its FDA-orphan-designated ALS treatment, NeuroNata-R, alongside its position as a leading domestic provider of toxicology and efficacy testing. It operates a resilient hybrid business model that pairs high-upside regenerative medicine R&D with stable, cash-generating CRO operations.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	30M	22M	19M	13M	-24.0%
EPS	-0.07	-0.46	-0.62	-0.59	—
Shares	40M	40M	40M	28M	-30.6%
Debt	12M	22M	31M	26M	28.3%
Equity	25M	13M	32M	36M	12.6%
Op CF	-5M	-10M	-14M	-9M	—
Inv CF	37M	-6M	-16M	-629,708	—
Fin CF	-34M	17M	29M	10M	—

PRICE (1M)-22.6%

SMA 50SMA 200

$1.72

RSI (14)

14.5

52W High

$4.02

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-33.4%20.3

ROE

-66.1%13.0

GP/Assets

-3.8%8.0

Op. Margin

-137.7%15.5

FCF/Assets

-6.8%32.7

Piotroski

—7.2

Int. Cover

-14.9x21.6

D/E Ratio

0.78x19.9

Current Ratio

0.28x1.0

Value

P/E (TTM)

—N/A

EV/EBITDA

-8.0x78.8

P/FCF

—N/A

P/B

1.3x71.6

P/S

3.9x47.9

Div Yield

—N/A

Momentum

52W High %

43%15.5

RS 6M

-67%15.2

SMA 50/200

1.34x95.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$69M

P/E (Forward)

—

Gross Margin

-23.9%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 166480.KQ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
166480.KQ	CORESTEMCHEMON Inc.(you)	$69M	9	STRONG SELL
456070.KQ	ENCell	$63M	5	STRONG SELL
235980.KQ	MedPacto, Inc.	$80M	6	STRONG SELL
389030.KQ	GENINUS Inc.	$74M	14	STRONG SELL
011000.KS	GeneOne Life Science, Inc.	$68M	1	STRONG SELL
203400.KQ	ABION Inc.	$54M	2	STRONG SELL
095700.KQ	Genexine, Inc.	$111M	7	STRONG SELL
323990.KQ	Vaxcell-Bio Therapeutics Co., Ltd.	$88M	2	STRONG SELL
048530.KQ	iNtRON Biotechnology, Inc.	$53M	17	STRONG SELL
321550.KQ	TiumBio Co., Ltd.	$127M	7	STRONG SELL

Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%

CORESTEMCHEMON Inc. (166480.KQ) — Stock Score Summary

CORESTEMCHEMON Inc. (166480.KQ) has a MoatMap StockRank of 9/100 based on Quality (15/100), Value (45/100), and Momentum (33/100) factor scores. The current signal is STRONG SELL. CORESTEMCHEMON is a South Korean stem cell biotech and CRO. It lacks the scale, global regulatory validation, and pricing power required to play our CDMO theme, and its extremely low quality score (15) is a major red flag.

Key Financial Metrics

Price	$1.72
Market Cap	$69M
Price/Book	1.30
Return on Equity	-66.1%
Return on Invested Capital	-33.4%
Debt/Equity	77.79
Gross Margin	-23.9%
Operating Margin	-137.7%
Revenue Growth	-29.0%
Free Cash Flow	$-3K

CORESTEMCHEMON Inc. operates in the Biotechnology industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is CORESTEMCHEMON Inc.’s (166480.KQ) StockRank?: MoatMap’s StockRank for CORESTEMCHEMON Inc. (166480.KQ) is 9/100, with a Strong Sell signal. It is a composite of Quality (15), Value (45), and Momentum (33) factor ranks across MoatMap’s 20,000+ stock universe.
Does CORESTEMCHEMON Inc. have an economic moat?: CORESTEMCHEMON Inc. (166480.KQ) has a Quality factor score of 15/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is CORESTEMCHEMON Inc. a buy, hold, or sell?: MoatMap’s current signal for CORESTEMCHEMON Inc. (166480.KQ) is Strong Sell, based on a StockRank of 9/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is CORESTEMCHEMON Inc. in?: CORESTEMCHEMON Inc. (166480.KQ) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).